This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snell, N. J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snell, N. J. C.

 Previous Article

Journal of Virology, September 2004, p. 10211, Vol. 78, No. 18
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.18.10211.2004

LETTER TO THE EDITOR

Ribavirin Therapy for Nipah Virus Infection


arrow
LETTER
 
The January 2004 issue of the Journal of Virology contains a very interesting paper on protection of mice against lethal challenge with Nipah virus by vaccination and by passive transfer of antibody (2). However, in the Discussion the authors (referring to the Nipah virus epidemic which affected Malaysia in 1998) state that "ribavirin was tried on some patients but with no significant results." This statement is misleading and not supported by the two references cited (1, 3). One of these references refers to a review article that I wrote in 2001; the only mention of Nipah virus in this paper is a speculative statement that ribavirin might prove of value in the treatment of Nipah virus infection, based solely on the known activity of this agent against other paramyxoviruses (3). The other paper cited (1) reported an open-label study of ribavirin in 140 patients with Nipah virus encephalitis, using as controls 54 similar patients who were managed before ribavirin became available or who refused treatment. Mortality in the ribavirin-treated limb was 32%, compared with 54% in the controls (P = 0.011). Duration of ventilation and total hospital stay were both significantly shorter in the ribavirin group (P = 0.0002 and <0.0001, respectively). There was a nonsignificant trend to a reduction in neurological deficits in survivors who received ribavirin (P = 0.17).

There is certainly a paucity of blinded, randomized, controlled trial data on the efficacy of ribavirin in this condition, but it is clearly quite incorrect, on the basis of the references cited, to say that ribavirin was ineffective, and it would be a pity if potential researchers who read this article were deterred from studying the effects of ribavirin more thoroughly.


arrow
REFERENCES
 
    1
  1. Chong, H.-T., A. Kamarulzaman, C.-T. Tan, K.-J. Goh, T. Thayaparan, S. R. Kunjapan, N.-K. Chew, K.-B. Chua, and S.-K. Lam. 2001. Treatment of acute Nipah virus encephalitis with ribavirin. Ann. Neurol. 49:810-813.[CrossRef][Medline]
    2. 2
  2. Guillaume, V., H. Cantamin, P. Loth, M.-C. Georges-Courbot, A. Lefeuvre, P. Maraianneau, K. B. Chua, S. K. Lam, R. Buckland, V. Deubel, and T. F. Wild. 2004. Nipah virus: vaccination and passive protection studies in a hamster model. J. Virol. 78:834-840.[Abstract/Free Full Text]
    3. 3
  3. Snell, N. J. C. 2001. Ribavirin—current status of a broad-spectrum antiviral agent. Exp. Opin. Pharmacother. 2:1317-1324.[CrossRef][Medline]
N. J. C. Snell
Experimental Medicine,
AstraZeneca R&D Charnwood,
Loughborough, United Kingdom
E-mail: noel.snell{at}astrazeneca.com.


Editor’s Note:


arrow
LETTER 
 
The authors of the published article declined to respond.

Journal of Virology, September 2004, p. 10211, Vol. 78, No. 18
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.18.10211.2004





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snell, N. J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snell, N. J. C.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»